Novolink Health (Previously Duxlink Health), A Division of Cardiovascular Associates of America, Sunrise, Florida, USA.
University of California Los Angeles David Geffen School of Medicine, Department of Medicine, Los Angeles, California, USA.
Clin Cardiol. 2024 Jun;47(6):e24302. doi: 10.1002/clc.24302.
There is no widely accepted care model for managing high-need, high-cost (HNHC) patients. We hypothesized that a Home Heart Hospital (H3), which provides longitudinal, hospital-level at-home care, would improve care quality and reduce costs for HNHC patients with cardiovascular disease (CVD).
To evaluate associations between enrollment in H3, which provides longitudinal, hospital-level at-home care, care quality, and costs for HNHC patients with CVD.
This retrospective within-subject cohort study used insurance claims and electronic health records data to evaluate unadjusted and adjusted annualized hospitalization rates, total costs of care, part A costs, and mortality rates before, during, and following H3.
Ninety-four patients were enrolled in H3 between February 2019 and October 2021. Patients' mean age was 75 years and 50% were female. Common comorbidities included congestive heart failure (50%), atrial fibrillation (37%), coronary artery disease (44%). Relative to pre-enrollment, enrollment in H3 was associated with significant reductions in annualized hospitalization rates (absolute reduction (AR): 2.4 hospitalizations/year, 95% confidence interval [95% CI]: -0.8, -4.0; p < 0.001; total costs of care (AR: -$56 990, 95% CI: -$105 170, -$8810; p < 0.05; and part A costs (AR: -$78 210, 95% CI: -$114 770, -$41 640; p < 0.001). Annualized post-H3 total costs and part A costs were significantly lower than pre-enrollment costs (total costs of care: -$113 510, 95% CI: -$151 340, -$65 320; p < 0.001; part A costs: -$84 480, 95% CI: -$121 040, -$47 920; p < 0.001).
Longitudinal home-based care models hold promise for improving quality and reducing healthcare spending for HNHC patients with CVD.
目前尚无广泛接受的管理高需求、高费用(HNHC)患者的护理模式。我们假设,提供纵向、医院级别的家庭护理的家庭心脏医院(H3)将改善心血管疾病(CVD)HNHC 患者的护理质量并降低成本。
评估接受 H3 治疗(提供纵向、医院级别的家庭护理)与 CVD HNHC 患者的护理质量和成本之间的关联。
这项回顾性自身对照队列研究使用了保险索赔和电子健康记录数据,以评估 H3 治疗前后的未经调整和调整后的年化住院率、护理总成本、A 部分成本和死亡率。
在 2019 年 2 月至 2021 年 10 月期间,94 名患者被纳入 H3 治疗。患者的平均年龄为 75 岁,50%为女性。常见合并症包括充血性心力衰竭(50%)、心房颤动(37%)、冠状动脉疾病(44%)。与入组前相比,入组 H3 治疗与年化住院率显著降低相关(绝对降低(AR):2.4 次住院/年,95%置信区间[95%CI]:-0.8,-4.0;p<0.001;护理总成本(AR):-56990 美元,95%CI:-105170 美元,-8810 美元;p<0.05;A 部分成本(AR):-78210 美元,95%CI:-114770 美元,-41640 美元;p<0.001)。H3 治疗后的年化总费用和 A 部分费用明显低于入组前的费用(护理总成本:-113510 美元,95%CI:-151340 美元,-65320 美元;p<0.001;A 部分费用:-84480 美元,95%CI:-121040 美元,-47920 美元;p<0.001)。
纵向家庭护理模式有望改善 CVD HNHC 患者的护理质量并降低医疗保健支出。